Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideGILDGilead Sciences
FinDog View：Neutral
ZBHZimmer Biomet
FinDog View：Neutral
| Metric | GILD | ZBH |
|---|
| Close | 170.68 | 94.52 |
| Market Cap | $213B | $18.8B |
| 1M | +14.51% | +6.41% |
| P/E (TTM) | — | 22.3 |
| Forward P/E | 22.0 | 10.5 |
| P/E 5-Yr Percentile | — | 28 |
| P/S | 7.0 | 2.1 |
| P/B | 17.9 | 1.4 |
| Dividend Yield | 3.98% | 1.04% |
| Latest Quarter Revenue | $8.3B | $2.2B |
| Revenue YoY | +6.8% | +4.8% |
| Gross Margin | 81.1% | 70.8% |
| Latest Quarter EPS | 1.94 | 1.03 |
| Avg Post-Earnings Move | ±3.8% | ±2.1% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.57% | 5.00% |
| 90-Day Net Insider Buying | −$15.9M | −$0.82M |
GILD · Revenue, Last 8 Quarters ($B)
ZBH · Revenue, Last 8 Quarters ($B)
